Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ: AGIO · Real-Time Price · USD
28.32
-1.65 (-5.51%)
May 6, 2025, 4:00 PM EDT - Market closed
-5.51%
Market Cap 1.64B
Revenue (ttm) 37.04M
Net Income (ttm) 665.99M
Shares Out 57.92M
EPS (ttm) 11.45
PE Ratio 2.47
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 836,972
Open 29.65
Previous Close 29.97
Day's Range 27.82 - 29.93
52-Week Range 23.42 - 62.58
Beta 0.77
Analysts Buy
Price Target 56.00 (+97.74%)
Earnings Date May 1, 2025

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2013
Employees 488
Stock Exchange NASDAQ
Ticker Symbol AGIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $56.0, which is an increase of 97.74% from the latest price.

Price Target
$56.0
(97.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...

4 days ago - GlobeNewsWire

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Br...

5 days ago - Seeking Alpha

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia,  with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Dis...

5 days ago - GlobeNewsWire

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea...

19 days ago - GlobeNewsWire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea...

2 months ago - GlobeNewsWire

Agios to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...

2 months ago - GlobeNewsWire

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce...

2 months ago - GlobeNewsWire

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO C...

2 months ago - Seeking Alpha

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND ®) for the Treatment of Adult Patients with  Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S.,  European U...

2 months ago - GlobeNewsWire

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –

2 months ago - GlobeNewsWire

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas...

3 months ago - GlobeNewsWire

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of car...

Other symbols: BIIB
4 months ago - Business Wire

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce...

4 months ago - GlobeNewsWire

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas...

4 months ago - GlobeNewsWire

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –

5 months ago - GlobeNewsWire

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-prog...

6 months ago - GlobeNewsWire

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communicati...

6 months ago - Seeking Alpha

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma...

6 months ago - GlobeNewsWire

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce...

7 months ago - GlobeNewsWire

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...

8 months ago - GlobeNewsWire

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...

8 months ago - GlobeNewsWire

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 tria...

9 months ago - Seeking Alpha

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Bill...

9 months ago - GlobeNewsWire

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to

9 months ago - Benzinga

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications...

9 months ago - Seeking Alpha